08/02/2026
The Cardio-Renal Metabolic (CRM) National Policy Review Workshop was held from 4-5 February 2026 at Le Meridien Putrajaya. The programme held in collaboration with the Ministry of Health's CRM Sector, Disease Control Division and with the support of Boehringer Ingelheim (Malaysia) convened policymakers, clinicians, and health-system stakeholders to review Malaysia’s existing cardiovascular, renal, metabolic and nutrition strategies, identify implementation gaps, and strengthen policy alignment.
It built on outcomes from the Sesi Pemukiman Pengurusan Tertinggi KKM & Menteri Kesihatan and a recent commissioned report on CRM-related policies. Representatives included officers from the Medical Development Division, Nutrition Division, State Health Officers, National Institutes of Health, National Cancer Institute and Institute of Public Health.
The workshop opened with remarks from Dr. Thahirahtul Asma' Zakaria on behalf of Dr Noraryana Hassan, Director of Disease Control Division, MOH.
A presentation on key findings from ACCESS Health International’s report "Advancing Cardio-renal-metabolic health in Malaysia: Connected risks, coordinated solutions", including the burden of multi-morbidity and projected economic impact, followed by a structured discussion of policy and implementation gaps—covering screening, referral pathways, primary care capacity, and alignment across NCD strategies, kicked off the workshop.
The day concluded with breakout discussions across three themes: (1) CRM strategy and policy alignment, (2) integrated screening and referral pathways, and (3) primary care strengthening and public–private models to expand diagnostics, chronic disease management, and digital integration.
Day two began with a recap and an overview of cardiorenal metabolic disease in Malaysia led by Dr Sivarajan Ramasamy (CRM Sector, Disease Control Division), followed by updates on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) (Prof. Dr. Chan Wah Kheong, Universiti Malaya Medical Centre), chronic kidney disease (Dr. Shahnaz Shah Firdaus Khan, HTAR), and cardiovascular disease (Dr. Sivarajan).
Participants then moved into concurrent group work to identify opportunities for initiatives over the next five years, including disease-specific and cross-cutting discussions (MAFLD, CKD, CVD, and salt reduction strategies).
An integration segment consolidated each group’s 3–4 priority actions, with a shortlist of actionable policy directions for consideration in upcoming policy cycles.